改善睡眠障碍有助于降血压

目的研究治疗睡眠障碍对高血压患者血压的影响。方法高血压同时有睡眠障碍患者261例在常规降压药物治疗基础上随机分为治疗组(132例)和对照组(129例),分别采用舒乐安定和安慰剂治疗,并观察睡眠障碍量表(SDRS)、汉密尔顿焦虑量表(HAMA)、治疗药物不良反应量表(TESS)以及患者血压的变化:坐位舒张压(SiDBP)和坐位收缩压(SiSBP)谷值与基线血压的变化、目标血压(<140/90mmHg)达标率等。结果舒乐安定对患者入睡困难的疗效明显,对早段失眠症状的减分比较明显,并能改善睡眠质量,延长睡眠时间,达到患者的生理睡眠要求。其有效率为66.7%,疗效优于安慰剂组(P<0.01)。同时舒乐安定也能显著降低HAMA分值,改善患者焦虑的症状,其疗效也优于安慰剂(P均<0.05)。随着睡眠、焦虑的改善,治疗组患者的血压舒张压(DBP)和收缩压(SBP)]较对照组明显下降(P均<0.05),目标血压(<140/90mmHg)的达标率也显著高于对照组(P<0.01)。结论舒乐安定治疗高血压患者睡眠障碍、焦虑有显著疗效。睡眠障碍可严重影响高血压患者的血压变化,改善患者的睡眠有利于改善患者的血压状态。

Improvement of Somnipathy is An Effectively Adjunctive Treatment for Antihypertensive Therapy

Objective To study the impact of insomnic treatment on blood pressure in the patients with hypertension. Methods Two hundren sixty-one cases of hypertension complicated with somnipathy were randomized to receive standard antihypertensive treatment in addition with estazolam(n=132) or adding placebo(n=129). Blood pressure, the scores of sleep dysfunction rating scale(SDRS) and Hamilton anxiety rating scale(HAMA) were compared before and after the treatment. Results The scores of SDRS and HAMA in the estazolam group were significantly reduced compared with those in the control group (P<0.01 and 0.05). The efficacy rate of estazolam group in treating somnipathy was 66.7%, significantly higher than that (16.3%) in control group (P<0.01). Blood pressure in estazolam group was also significantly reduced at end of treatment with no changes in control group. Conclusion Estazolam was shown to be a good efficacy in treating somnipathy as an adjunctive treatment for patients with hypertension.